Results 21 to 30 of about 77,471 (339)
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Nature Medicine, 2022 Public neoantigens (NeoAgs) represent an elite class of shared cancer-specific epitopes derived from recurrently mutated driver genes. Here we describe a high-throughput platform combining single-cell transcriptomic and T cell receptor (TCR) sequencing ...Smita S. Chandran, Jiaqi Ma, M. Klatt, F. Dündar, C. Bandlamudi, P. Razavi, H. Wen, B. Weigelt, P. Zumbo, Si-Ning Fu, Lauren B. Banks, Fei Yi, Enric Vercher, Iñaki Etxeberria, Watchain D. Bestman, A. Da Cruz Paula, I. Aricescu, A. Drilon, D. Betel, D. Scheinberg, B. Baker, C. Klebanoff +21 moresemanticscholar +1 more sourceMegalencephaly syndromes: exome pipeline strategies for detecting low-level mosaic mutations [PDF]
, 2014 Two megalencephaly (MEG) syndromes, megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicrogyriapolydactyly?-hydrocephalus(MPPH), have recently been defined on the basis of physical and neuroimaging features.Cross, Nicholas C. P., Hidalgo-Curtis, Claire, Claire Hidalgo-Curtis (518402), Score, Joannah, Gibson, Jane, Sarah Ennis, Jane Gibson, I Karen Temple, Andrew Collins, Andrew Collins (63814), Nicola Foulds, Paula Aranaz (518400), Foulds, Nicola, Claire Hidalgo-Curtis, I. Karen Temple (518404), Sarah Ennis (435142), David O. Robinson (518403), Temple, I. Karen, William J Tapper, Paula Aranaz, Collins, Andrew, Joannah Score, Nicola Foulds (518399), Joannah Score (518401), Tapper, William J., Robinson, David O., William J. Tapper (518398), Ennis, Sarah, David O Robinson, Aranaz, Paula, Nicholas C P Cross, Jane Gibson (497328), Nicholas C. P. Cross (185184) +32 morecore +1 more sourceClinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant
Clinical Cancer Research, 2022 Purpose: PIK3CA and ESR1 mutations have been implicated in resistance to endocrine therapy (ET) in HR+, HER2− advanced breast cancer (ABC). Inhibition of CDK4 and 6 has been hypothesized as a therapeutic strategy to overcome endocrine resistance in ...S. Tolaney, M. Toi, P. Neven, J. Sohn, E. Grischke, A. Llombart-Cussac, H. Soliman, Hong Wang, S. Wijayawardana, V. Jansen, L. Litchfield, G. Sledge +11 moresemanticscholar +1 more sourceEnergy balancing by fat Pik3ca [PDF]
Adipocyte, 2014 Obesity is often associated with systemic insulin resistance, and the decline of insulin sensitivity marks the progression of obesity into a disease state. We recently generated a mouse with adipose-specific ablation of the p110α phosphoinositide 3-kinase (PI3K) catalytic subunit to model insulin resistance in this organ.Victoria Lb, Nelson, Lisa M, Ballou, Richard Z, Lin +2 moreopenaire +2 more sourcesEvaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. [PDF]
, 2011 BACKGROUND: Somatic mutations in phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) are frequent in breast tumours and have been associated with oestrogen receptor (ER) expression, human epidermal growth factor receptor-2 overexpression, lymph ...Dite, G S, S Chanock, Noh, D-Y., Severi, G., Sangrajrang, S., Hein, R, Yoo, K-Y, J Wang, Wang, J., Pooley, K A, Anton-Culver, H., Rogov, Y.I., A Ziogas, Hein, A, Kosma, V.M., Brock, I W, S Manoukian, Meindl, A., S Sangrajrang, Dunning, A.M., R L Milne, Bartrar, CR, R Winqvist, S S Cross, Perez, J.I.A., Anton Culver, H., Ekici, A. B., Garcia Closas, M., Noh, D.Y., G G Giles, M W Beckmann, Silva, I. dos Santos, Hopper, JL, Broeks, A., Vachon, C M, N Johnson, Hopper, J L, Humphreys, M K, Bruening, T., Wang-Gohrke, S., Tollenaar, Robert A. E. M., Cross, SS, Kosma, V-M, Johnson, N., Bonanni, B, Milne, R L, Vachon, CM, M Bremer, Sawyer, E, Kataja, V, Mulligan, A.M., Easton, D F, Kosma, V-M., Chenevix Trench, G., P Schürmann, A Miron, L Baglietto, Miron, A, Lindblom, A., E M John, I W Brock, McKay, J, Kang, D., Bogdanova, N, Johnson, N, Apicella, C., Garcia-Closas, M., Van 't Veer, L. J., Hartikainen, J, Pylkaes, K., G S Dite, P Brennan, Hopper, J. L., Van 't Veer, LJ, Pooley, KA, Fredericksen, Z, Milne, R.L., Hopper, J.L., Cox, A, Pooley, K. A., Hillemanns, P., Wang-Gohrke, S, Kerin, M.J., John, E M, Rogov, Y. I., Zalutsky, J. V., Olson, J, McLean, CA, Anton-Culver, H, G D Thomas, Pooley, K.A., Hunter, D J, Grip, M, V-M Kosma, A Meindl, X Wang, N Bogdanova, BAGLIETTO, LAURA, Tomlinson, I, E Sawyer, Giles, GG, A M Dunning, Antonenkova, N, Pérez, JA, Schmidt, M K, Giles, G G, N Antonenkova, B Bonanni, Pharoah, P.P., Southey, M C, Chenevix-Trench, G, Invest, kConFab, GENICA Network, Schmidt, M. K., Hunter, DJ, Knight, J.A., Ko, YD, Mulligan, A M, Baglietto, L, Rogov, YI, V Gabrieau, Couch, FJ, Beckmann, M W, Knight, J A, Fasching, PA, J Peto, Meindl, A, Severi, G, Gibson, L., Burwinkel, B., Y I Rogov, Benítez, J, J McKay, Tomlinson, Ian, John, E. M., P P Pharoah, Lissowska, J, Noh, DY, Brüning, T., D-Y Noh, Glendon, G., Peterlongo, P, Noh, D. Y., Fredericksen, Z., Milne, RL, Beckmann, MW, Cross, S.S., Kosel, M, Manoukian, S., Schürmann, P, Chanock, S., Cerhan, J, Jukkola-Vuorinen, A, Fasching, P A, Australian Ovarian Cancer Study Group, Hoover, R. N., Vachon, C. M., I Andrulis, Rogov, Y I, Schmidt, M.K., H Anton-Culver, Dörk, T., P Hillemanns, Giles, G.G., Ekici, A B, Hoover, R.N., Schmutzler, RK, F J Couch, Australian Ovarian Cancer Study Gr, Peto, J., C Apicella, Couch, F.J., Hillemanns, P, Mannermaa, A., Brock, I.W., J Chang-Claude, Pylkäs, K, Van 't Veer, L.J., Cross, S. S., Chen, X, Winqvist, R, Hamann, U., Chang-Claude, J., Brennan, P, Baglietto, L., Kosma, V. M., Beckmann, M. W., Veer, L.J. van 't, Wang, X., kConFab Invest, Van T Veer, LJ, Van 't Veer, L. J., Dite, GS, S Margolin, Couch, F J, Jukkola-Vuorinen, A., Bartrar, C R, Dörk, T, Bremer, M, Hein, A., Dunning, A M, D Kang, D J Hunter, Manoukian, S, González-Neira, A, Doerk, T., Benitez, J., Thomas, GD, Sawyer, E., Hamann, U, T Dörk, V Kataja, Thomas, G. D., Dunning, A. M., Milne, R. L., I dos Santos Silva, Ko, Y D, A González-Neira, Tomlinson, I., Zalutsky, J V, M Grip, McLean, C A, Apicella, C, Gonzalez-Neira, A., Schmutzler, R. K., Pharoah, P P, null null, I Tomlinson, G Glendon, Stevens, K N, L J Van ‘t Veer, Schuermann, P., R N Hoover, Mclean, C. A., John, EM, Bartrar, C.R., Hunter, D.J., Mulligan, AM, C R Bartrar, Wang, J, Fasching, P.A., Ekici, A.B., Southey, M. C., Van ‘t Veer, LJ, Ziogas, A, Zalutsky, JV, Lissowska, J., Wang, X, Hoover, RN, M Garcia-Closas, Dunning, AM, Broeks, A, Burwinkel, B, Brock, IW, John, E.M., Easton, DF, Knight, J. A., M K Humphreys, Antonenkova, N., J A Knight, Tollenaar, RAEM, Kang, D, Mulligan, A. M., Kerin, M. J., Chang Claude, J., K-Y Yoo, M C Southey, Giles, G. G., Miron, A., Olson, J., Vachon, C.M., Humphreys, MK, Southey, M.C., S Wang-Gohrke, Chang-Claude, J, J Olson, Sangrajrang, S, Mckay, J., A Cox, Silva, I.D.S., V S Pankratz, Brennan, P., A B Ekici, Noh, D-Y, Jukkola Vuorinen, A., X Chen, Bremer, M., Ziogas, A., Pankratz, V. S., G Elliott, Schmutzler, R.K., Cerhan, J., Ekici, AB, Group, AOCS, Couch, F. J, K N Stevens, Van ‘t Veer, L J, Network, GENICA, A Broeks, A Mannermaa, A Lindblom, L Bernard, Peto, J, dos Santos Silva, I, M Kosel, Bonanni, B., A Jukkola-Vuorinen, Elliott, G., B Burwinkel, L Gibson, Easton, D. F., Yoo, KY, Knight, JA, Z Fredericksen, Grip, M., Gabrieau, V, M J Kerin, Peterlongo, P., Hoover, R N, Beckmann, M.W., J Cerhan, Bogdanova, N., Schürmann, P., Couch, F. J., Yoo, K.Y., R K Schmutzler, Gibson, L, J L Hopper, Lindblom, A, J Benítez, Kosel, M., C M Vachon, G Severi, González Neira, A., Margolin, S., K A Pooley, Humphreys, M. K., Pharoah, P. P., Stevens, K. N., Southey, MC, Brüning, T, Pharoah, PP, Dite, G. S., P Peterlongo, Bartrar, C. R., Elliott, G, A Hein, Kerin, MJ, Yoo, K-Y., Hartikainen, J., Pérez, J. A., R A E M Tollenaar, Dite, G.S., JI Arias Pérez, Garcia-Closas, M, Kosma, VM, Tollenaar, RA, G Chenevix-Trench, Bernard, L., Brock, I. W., Kerin, M J, Pankratz, V S, dos Santos Silva, I., Thomas, G D, J Hartikainen, Stevens, K.N., A M Mulligan, Wang Gohrke, S., Perez, J. I. Arias, Y D Ko, D F Easton, Chanock, S, C A McLean, Humphreys, M.K., M K Schmidt, Gabrieau, V., Arias Pérez, JI, Andrulis, I, Margolin, S, Pankratz, VS, Stevens, KN, Zalutsky, J.V., Ko, Y. D., Mannermaa, A, McLean, C.A., Tollenaar, R. A. E. M., Tollenaar, R.A.E.M., Cox, A., Andrulis, I., Schmutzler, R K, R Hein, Winqvist, R., Cross, S S, Pankratz, V.S., P A Fasching, Chen, X., Easton, D.F., Bernard, L, Ko, Y.D., Pylkäs, K., J Lissowska, Hunter, D. J., Fasching, P. A., Yoo, K. Y., J V Zalutsky, Silva, I.D., Kataja, V., Chenevix-Trench, G., T Brüning, Glendon, G, U Hamann, Hein, R., Thomas, G.D., Van T. Veer, L. J., K Pylkäs, Schmidt, MK, kConFab Investigators, Pérez, JI Arias, Hunter, David, Tollenaar, R A E M +419 morecore +1 more sourceAlpelisib for PIK3CA‐Mutated, Hormone Receptor–Positive Advanced Breast Cancer
New England Journal of Medicine, 2019 Background PIK3CA mutations occur in approximately 40% of patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer.F. André, E. Ciruelos, G. Rubovszky, M. Campone, S. Loibl, H. Rugo, H. Iwata, P. Conte, I. Mayer, B. Kaufman, T. Yamashita, Yen-Shen Lu, K. Inoue, Masato Takahashi, Z. Pápai, A. Longin, D. Mills, C. Wilke, S. Hirawat, D. Juric +19 moresemanticscholar +1 more sourceAlpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
Annals of Oncology, 2020 BACKGROUND
Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABC) and is associated F. André, E. Ciruelos, D. Juric, S. Loibl, M. Campone, I. Mayer, G. Rubovszky, T. Yamashita, B. Kaufman, Yung-Feng Lu, K. Inoue, Z. Pápai, M. Takahashi, F. Ghaznawi, D. Mills, M. Kaper, M. Miller, P. Conte, H. Iwata, H. Rugo +19 moresemanticscholar +1 more sourceNODAL/TGFβ signalling mediates the self-sustained stemness induced by PIK3CAH1047R homozygosity in pluripotent stem cells
Disease Models & Mechanisms, 2021 Activating PIK3CA mutations are known ‘drivers’ of human cancer and developmental overgrowth syndromes. We recently demonstrated that the ‘hotspot’ PIK3CAH1047R variant exerts unexpected allele dose-dependent effects on stemness in human pluripotent stem Ralitsa R. Madsen, James Longden, Rachel G. Knox, Xavier Robin, Franziska Völlmy, Kenneth G. Macleod, Larissa S. Moniz, Neil O. Carragher, Rune Linding, Bart Vanhaesebroeck, Robert K. Semple +10 moredoaj +1 more sourceGenetic heterogeneity and tissue-specific patterns of tumors with multiple PIK3CA mutations
Clinical Cancer Research, 2023 Purpose: To comprehensively characterize tissue-specific and molecular subclasses of multiple PIK3CA (multi-PIK3CA) mutations and assess their impact on potential therapeutic outcomes. Experimental Design: We profiled a pan-cancer cohort comprised of 352,S. Sivakumar, Dexter X. Jin, Ruchita Rathod, J. Ross, L. Cantley, M. Scaltriti, Jessica W. Chen, K. Hutchinson, T. Wilson, E. Sokol, N. Vasan +10 moresemanticscholar +1 more sourcePIK3CA mutations in vascular malformations [PDF]
Current Opinion in Hematology, 2019 Purpose of review Recently, it has been discovered that a subset of vascular malformations, of the lymphatic and venous type, are caused by oncogenic mutations in the PIK3CA gene. Now, efforts have been focused in the understanding of the molecular and cellular consequences of these mutations and the opportunities for novel ...Castillo, Sandra D., Baselga, Eulalia, Graupera, Mariona +2 moreopenaire +3 more sources
